Opinion|Videos|January 24, 2025
Future Directions and Research Priorities in BTKi Treatment Approaches
Panelists discuss how challenges in implementing emerging Bruton tyrosine kinase inhibitor (BTKi) regimens for treatment-naive patients with chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) may include issues related to access, cost, and patient adherence, and highlight the need for ongoing research and collaboration to optimize BTKi use and improve patient outcomes in both diseases.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What challenges do you anticipate in the implementation of these emerging BTKi regimens for treatment-naive patients with CLL or MCL, and how might these challenges be addressed?
- What are you most looking forward to seeing in the use of BTK inhibitors, and what are some key areas where you think further research and collaboration are needed to continue improving patient outcomes?
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
FDA Panel Backs 6 Peptides for Compounding
2
Oncology Leaders Call for Greater Collaboration to Advance Precision Medicine, Innovative Cancer Care
3
Teclistamab-Talquetamab Combo Cuts Myeloma Progression Risk by 89%
4
Study Shows Potential for Low-Dose CAR T, With Implications for Increased Access
5